Browsing by Subject "Biosimilar Pharmaceuticals"
Now showing items 1-3 of 3
-
Comparative immunogenicity assessment of biosimilars
(2019)The first anticancer biosimilars have entered clinical use, with many others under clinical development. Like all biologics, biosimilars may elicit unwanted immune responses that can significantly impact clinical efficacy ... -
Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review
(2019)Purpose: In observational studies of patients switched from stable treatment with an originator monoclonal antibody (mAb) to a biosimilar, higher rates of biosimilar discontinuation versus those observed in blinded switching ... -
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
(2018)Purpose: With the introduction of biosimilars of anticancer monoclonal antibodies (mAbs) in oncology, physicians are potentially confronted with the question whether it is clinically adequate to switch patients who are ...